Overview

This trial is active, not recruiting.

Condition breast cancer
Treatments exemestane, tamoxifen citrate
Phase phase 3
Sponsor International Breast Cancer Study Group
Collaborator National Cancer Institute (NCI)
Start date August 2003
End date June 2015
Trial size 2672 participants
Trial identifier NCT00066703, BIG-3-02, CDR0000316458, EU-20347, EUDRACT-2004-000168-28, IBCSG 25-02, NABCI-IBCSG-25-02

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
Beginning after the completion of adjuvant chemotherapy or approximately 6-8 weeks after the initiation of triptorelin, patients receive oral tamoxifen daily.
tamoxifen citrate
Given orally
(Experimental)
Beginning after the completion of adjuvant chemotherapy or approximately 6-8 weeks after the initiation of triptorelin, patients also receive oral exemestane daily.
exemestane
Given orally

Primary Outcomes

Measure
Disease-free survival
time frame: For first time at a median follow up approximately 5 years

Secondary Outcomes

Measure
Overall survival
time frame: For first time at a median follow up approximately 5 years
Breast cancer-free interval
time frame: For first time at a median follow up approximately 5 years
Distant recurrence-free interval
time frame: For first time at a median follow up approximately 5 years
Sites of first recurrence
time frame: For first time at a median follow up approximately 5 years

Eligibility Criteria

Female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed breast cancer - Completely resected disease - No clinically detectable residual loco-regional axillary disease - Prior surgery for primary breast cancer of 1 of the following types: - Total mastectomy with or without adjuvant radiotherapy - Breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins negative* for invasive disease and ductal carcinoma in situ) with planned radiotherapy NOTE: *If all other margins are clear a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed - Tumor confined to the breast and axillary nodes - Tumor detected in internal mammary chain nodes by sentinel node procedure and is not enlarged is allowed - Axillary lymph node dissection or a negative axillary sentinel node biopsy required - Patients with negative or microscopically positive axillary sentinel nodes are eligible - Positive sentinel nodes must have either axillary dissection or radiation of axillary nodes - No distant metastases - No locally advanced inoperable breast cancer, including any of the following: - Inflammatory breast cancer - Supraclavicular node involvement - Enlarged internal mammary nodes (unless pathologically negative) - Bilateral synchronous invasive breast cancer allowed if disease meets all other eligibility criteria - No prior ipsilateral or contralateral invasive breast cancer - Hormone receptor status: - Estrogen and/or progesterone receptor positive - At least 10% of the tumor cells positive by immunohistochemistry - If > 1 breast tumor, each tumor must be hormone receptor positive PATIENT CHARACTERISTICS: Age - Premenopausal Sex - Female Menopausal status - Premenopausal - Estradiol in the premenopausal range after prior surgery OR meets the following criteria: - Menstruating regularly for the past 6 months - Has not used any form of hormonal treatment (including hormonal contraception) within the past 6 months Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - No systemic hepatic disease that would preclude prolonged follow-up Renal - No systemic renal disease that would preclude prolonged follow-up Cardiovascular - No systemic cardiovascular disease that would preclude prolonged follow-up - No prior thrombosis (e.g., deep vein thrombosis) and/or embolism unless patient is medically suitable Pulmonary - No systemic pulmonary disease that would preclude prolonged follow-up Other - Not pregnant or nursing - Fertile patients must use effective nonhormonal contraception - No history of noncompliance to medical regimens - No other nonmalignant systemic disease that would preclude prolonged follow-up - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ, contralateral or ipsilateral carcinoma in situ of the breast, or other nonrecurrent invasive nonbreast malignancy, including any of the following: - Stage I papillary thyroid cancer - Stage IA carcinoma of the cervix - Stage IA or B endometrioid endometrial cancer - Borderline or stage I ovarian cancer - No psychiatric, addictive, or other disorder that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - Prior or concurrent neoadjuvant or adjuvant trastuzumab allowed Chemotherapy - No prior neoadjuvant or adjuvant chemotherapy Endocrine therapy - No prior tamoxifen, other selective estrogen-receptor modulators (SERMs) (e.g., raloxifene), or hormone replacement therapy for more than 1 year before breast cancer diagnosis - No prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer - No concurrent oral or transdermal hormonal therapy - No other concurrent estrogen, progesterone, or androgens - No other concurrent aromatase inhibitors - No concurrent oral or other hormonal contraceptives (i.e., implants or depot injections) Radiotherapy - See Disease Characteristics - No prior ovarian radiotherapy Surgery - See Disease Characteristics - No prior bilateral oophorectomy Other - No concurrent bisphosphonates, except in the following cases: - Bone density is at least 1.5 standard deviations below the young adult normal mean - Participation in a randomized clinical study testing bisphosphonates in the adjuvant breast cancer setting - No other concurrent investigational agents

Additional Information

Official title A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
Description OBJECTIVES: - Compare the disease-free and overall survival of premenopausal women with endocrine-responsive breast cancer when treated with triptorelin and exemestane vs triptorelin and tamoxifen. - Compare the quality of life, including late side effects of early menopause, of patients treated with these regimens. - Compare the sites of first treatment failure in patients treated with these regimens. - Compare the incidence of second (non-breast) malignancies in patients treated with these regimens. - Compare causes of death without cancer event OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, concurrent adjuvant chemotherapy (yes vs no), and number of positive axillary and/or internal mammary lymph nodes (0 vs 1 or more). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive triptorelin intramuscularly on day 1 every 28 days. Patients in the adjuvant chemotherapy stratum receive chemotherapy concurrently with triptorelin for at least 2 months (if anthracycline is included) or at least 4 months (if no anthracycline is included). Beginning after the completion of chemotherapy or approximately 6-8 weeks after the initiation of triptorelin, patients receive oral tamoxifen daily. - Arm II: Patients receive triptorelin as in arm I. Beginning after the completion of adjuvant chemotherapy or approximately 6-8 weeks after the initiation of triptorelin, patients also receive oral exemestane daily. In both arms, treatment continues for 5 years in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, every 6 months for 2 years, and annually for 3 years. Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 2,639 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by International Breast Cancer Study Group.